Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditya Medisales Ltd Sun climbs 2% on entering Chinese markets
Shares of Sun Pharma traded 1.42 per cent up at Rs 408.50 on BSE. Sun Pharmaceutical Industries Ltd - 524715 - Closure of Trading Window
This is to inform you that in compliance with the Company''s Code of Conduct for Prevention of Insider Trading, the window closure for trading by Designated Persons of the Company shall be with effect from Monday, 1st July, 2019 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended 30th June, 2019. The date of Board Meeting of the Company for declaration of the financial results for the quarter ended on 30th June, 2019 will be intimated in due course. This is for your information and record. Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to License Agreement with China Medical System Holdings for Cyclosporine A eye drops in Greater China, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to License Agreement with China Medical System Holdings for Tildrakizumab in China, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Sun Pharmaceutical Industries Ltd - 524715 - Intimation Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the details of related party transactions on consolidated basis for the half year ended 31st March, 2019 in the format specified in the relevant accounting standards for annual results. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Valia SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd Sun Pharmaceutical Industries Ltd - 524715 - Clarification / Confirmation On News Item
With reference to your email dated June 21, 2019 seeking clarification on the news item in https://www.business-standard dated 21-Jun-2019, captioned 'Sun Pharmaceutical gets four observations for Halol facility in Gujarat', we hereby submit our responses as follows: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. Response - The US FDA conducted a Pre-Approval Inspection (PAI) of Sun Pharmaceutical Industries Ltd.'s Halol facility (Gujarat, India) from June 03, 2019 to June 11, 2019. At the conclusion of the inspection, the agency issued a Form 483, with four observations. The Company will be submitting its response on the observations to the US FDA within 15 business days. Sun Pharma is committed to addressing these observations promptly. b) Whether company are aware of any information that has not been announced to the Exchanges under regulation 30 of the SEBI (LODR) Regulations, 2015. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under regulation 30 of the SEBI (LODR) Regulations, 2015. Response - No. c) The material impact of this article on the Company. Response - There is no material impact of this article on the Company. Kindly let us know in case you require any further clarification.